Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

(Bloomberg) -- Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots away from consumer health to focus on fast-growing ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

L’Oreal OR0.54%increase; green up pointing triangle will sell part of its stake in Sanofi SAN 0.43%increase; green up pointing triangle back to the French pharmaceutical company for 3 billion ...

Der französische Pharmagigant Sanofi will das Geschäft mit rezeptfreien Medikamenten an einen amerikanischen Finanzinvestor verkaufen. Zu dem Paket gehört auch das beliebteste Schmerzmittel des ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

Die Sanofi Dividende wird für das vergangene Geschäftsjahr auf der aktuellen Hauptversammlung von Sanofi festgelegt. Der Vorstand von Sanofi macht dabei zunächst einen Vorschlag für die Sanofi ...

Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies.